-
1 month ago | 00417-9&sz=64)
cell.com | Kirstine Ravn |Jonas Meisner |Lasse Danielsen |Michael Eriksen Benros |Thorfinn Sand Korneliussen |Martin Sikora | +6 more
Keywords CCR5 CCR5delta32 HIV-1 infection resistance pleiotropy haplotype recombination ancient genomes evolution positive selection immune genes Introduction Humans have been exposed to pathogens over the course of our evolutionary history, and adaptations to them have left numerous signatures in our genomes.1,2,3 In recent years, evidence for selection has been found in genes involved in the development of tolerance against intracellular pathogens and in the inflammatory response against...
-
2 months ago | 
medrxiv.org | Simon Rasmussen |Michael Eriksen Benros |Enric Cristòbal Cóppulo
The authors have declared no competing interest. The work was supported by unrestricted grants from the Lundbeck Foundation (grant number R278-2018-1411 and R380-2021-1225) and from the Mental Health Services of the Capital Region of Denmark. S.R. was supported by the Novo Nordisk Foundation (NNF23SA0084103). I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
-
Feb 19, 2025 | 
nature.com | Lili Niu |Sara Stinson |Jens-Christian Holm |Simon Rasmussen |Torben Frøstrup Hansen
AbstractOur current understanding of the determinants of plasma proteome variation during pediatric development remains incomplete. Here, we show that genetic variants, age, sex and body mass index significantly influence this variation. Using a streamlined and highly quantitative mass spectrometry-based proteomics workflow, we analyzed plasma from 2,147 children and adolescents, identifying 1,216 proteins after quality control.
-
May 8, 2024 | 
biorxiv.org | Jakob Nybo Nissen |Pau Piera Lindez |Simon Rasmussen
AbstractNew methods for metagenomic binning are typically evaluated using benchmarking software, and become tuned to maximize whatever criterion is measured by the benchmark. Subtleties in benchmarking procedures can cause misleading evaluations, derailing method development. Differences between procedures used to evaluate binning tools make them hard to compare, which slows progress in the field.
-
May 1, 2024 | 
medrxiv.org | Jonas Meisner |Michael Eriksen Benros |Simon Rasmussen
The authors have declared no competing interest. Lundbeck Foundation (R380-2021-1225 and R278-2018-1411) and the Novo Nordisk Foundation (NNF14CC0001 and NNF23SA0084103). I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
-
Apr 1, 2024 | 
jrheum.org | Lykke M. Ørnbjerg |Kathrine Rugbjerg |Stylianos Georgiadis |Simon Rasmussen
RESULTSPatients. We included data on 12,262 biologic-naïve patients with PsA starting treatment with a first TNFi in a real-world setting between January 1, 2009, and December 31, 2018. Among these patients, 4329 patients later initiated a second TNFi and 1240 patients a third TNFi. Considering the first TNFi treatment course, etanercept was the most frequently prescribed drug (35% of patients), followed by adalimumab (30%), infliximab (17%), golimumab (13%), and certolizumab pegol (7%).
-
Mar 27, 2024 | 
mondaq.com | Rasmus Mandøe Jensen |Simon Rasmussen |Jónas Már Torfason
Recently, the ubiquitous activity of staking in
crypto-markets has been supplemented with so-called "liquid
staking". But liquid staking carries its own regulatory risks
which can be different and more significant than those applicable
to the token being staked. Below, investment services and
crypto-asset specialists from Plesner consider these important
risks.
-
Feb 9, 2024 | 
jrheum.org | Lykke M. Ørnbjerg |Kathrine Rugbjerg |Stylianos Georgiadis |Simon Rasmussen
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care Lykke M. Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, Simon H. Rasmussen, Lennart Jacobsson, Anne G. Loft, Florenzo Iannone, Karen M. Fagerli, Jiri Vencovsky, Maria J.
-
Jan 9, 2024 | 
jrheum.org | Lykke Midtbøll Ørnbjerg |Kathrine Rugbjerg |Stylianos Georgiadis |Simon Rasmussen
Patient-reported outcomes and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis treated with TNF-inhibitors in routine care Lykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, Simon Horskjær Rasmussen, Lennart Jacobsson, Anne Gitte Loft, Florenzo Iannone, Karen Minde Fagerli, Jiri Vencovsky, Maria José Santos, Burkhard Möller, Manuel Pombo-Suarez, Ziga Rotar, Bjorn Gudbjornsson, Ayse Cefle, Kari Eklund, Catalin Codreanu, Gareth Jones, Marleen van der...
-
Nov 15, 2023 | 
nature.com | Thit Mynster Kronborg |Henry E. Webel |Malene Barfod O’Connell |Karen Vagner Danielsen |Lise Hobolth |Flemming Bendtsen | +4 more
AbstractThe inflammatory activity in cirrhosis is often pronounced and related to episodes of decompensation. Systemic markers of inflammation may contain prognostic information, and we investigated their possible correlation with admissions and mortality among patients with newly diagnosed liver cirrhosis. We collected plasma samples from 149 patients with newly diagnosed (within the past 6 months) cirrhosis, and registered deaths and hospital admissions within 180 days.
